Proximal Fibulectomy for Giant Cell Tumours: What Works!

Common peroneal nerve Giant cell tumor Lateral collateral ligament Proximal fibulectomy

Journal

Indian journal of orthopaedics
ISSN: 0019-5413
Titre abrégé: Indian J Orthop
Pays: Switzerland
ID NLM: 0137736

Informations de publication

Date de publication:
Oct 2024
Historique:
received: 22 01 2024
accepted: 05 08 2024
medline: 26 9 2024
pubmed: 26 9 2024
entrez: 26 9 2024
Statut: epublish

Résumé

Giant cell tumor of bone (GCTB) is the most common primary tumor of proximal fibula. Because of its close proximity to vascular structures, common peroneal nerve (CPN) and attachment of lateral collateral ligament (LCL), proximal fibulectomy poses unique challenges. We analyzed oncological and functional outcome of patients who underwent proximal fibulectomy for GCTB of proximal fibula. Between January 2006 and December 2020, 23 patients underwent proximal fibulectomy for GCTB of proximal fibula, four were recurrent tumors. Mean resection length was 9 cm (5 to 15 cm). The LCL and biceps tendon were not reconstructed in 22 cases. The common peroneal nerve was sacrificed in seven patients including three recurrent cases. Functional status was assessed using the Musculoskeletal Tumour Society (MSTS) scoring system. There were two vascular complications and one infection. With 4 patients lost to follow up, mean follow up was 90 months (12 to 197). No patient had local or distant recurrence. Mean MSTS score was 26 (21 to 30). Eleven of 23 patients (48%) had loss of common peroneal nerve function with poorer functional outcome. No patient had symptoms suggestive of knee instability. Proximal fibulectomy is oncologically safe. Reconstruction of the LCL attachment is not mandatory and patients do not have symptomatic knee instability. Functional outcomes are compromised after sacrifice of common peroneal nerve and may be potentially improved with tendon transfers at index surgery.

Sections du résumé

Background UNASSIGNED
Giant cell tumor of bone (GCTB) is the most common primary tumor of proximal fibula. Because of its close proximity to vascular structures, common peroneal nerve (CPN) and attachment of lateral collateral ligament (LCL), proximal fibulectomy poses unique challenges. We analyzed oncological and functional outcome of patients who underwent proximal fibulectomy for GCTB of proximal fibula.
Material and methods UNASSIGNED
Between January 2006 and December 2020, 23 patients underwent proximal fibulectomy for GCTB of proximal fibula, four were recurrent tumors. Mean resection length was 9 cm (5 to 15 cm). The LCL and biceps tendon were not reconstructed in 22 cases. The common peroneal nerve was sacrificed in seven patients including three recurrent cases. Functional status was assessed using the Musculoskeletal Tumour Society (MSTS) scoring system.
Results UNASSIGNED
There were two vascular complications and one infection. With 4 patients lost to follow up, mean follow up was 90 months (12 to 197). No patient had local or distant recurrence. Mean MSTS score was 26 (21 to 30). Eleven of 23 patients (48%) had loss of common peroneal nerve function with poorer functional outcome. No patient had symptoms suggestive of knee instability.
Conclusion UNASSIGNED
Proximal fibulectomy is oncologically safe. Reconstruction of the LCL attachment is not mandatory and patients do not have symptomatic knee instability. Functional outcomes are compromised after sacrifice of common peroneal nerve and may be potentially improved with tendon transfers at index surgery.

Identifiants

pubmed: 39324085
doi: 10.1007/s43465-024-01231-2
pii: 1231
pmc: PMC11420405
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1474-1478

Informations de copyright

© The Author(s) 2024.

Déclaration de conflit d'intérêts

Conflict of interestThe authors have no relevant financial or non-financial interests to disclose.

Auteurs

Ashwin Prajapati (A)

Department of Surgical Oncology, Homi Bhabha National Institute, Tata Memorial Hospital, Parel, Mumbai, Maharashtra India.
Present Address: Department of Surgical Oncology, Marengo CIMS Cancer Centre, Off Science City Road, Sola, Ahmedabad, Gujarat India.

Harsha S S Tadala (HSS)

Department of Surgical Oncology, Homi Bhabha National Institute, Tata Memorial Hospital, Parel, Mumbai, Maharashtra India.
Present Address: Department of Surgical Oncology, Homi Bhabha Cancer Hospital and Research Centre, Tata Memorial Centre, Visakhapatnam, Andhra Pradesh India.

Ashish Gulia (A)

Department of Surgical Oncology, Homi Bhabha National Institute, Tata Memorial Hospital, Parel, Mumbai, Maharashtra India.
Present Address: Department of Surgical Oncology, Homi Bhabha Cancer Hospital & Research Centre, Tata Memorial Centre, Mohali, New Chandigarh, Punjab India.

Ajay Puri (A)

Department of Surgical Oncology, Homi Bhabha National Institute, Tata Memorial Hospital, Parel, Mumbai, Maharashtra India.

Classifications MeSH